Angola vs Mauritania: Death rate from cancer
Angola
45.17 deaths per 100,000 people
in 2021
Mauritania
44.32 deaths per 100,000 people
in 2021
Angola rank
167th
Mauritania rank
169th
Death rate from cancer over time
- Angola
- Mauritania
How they compare
Angola currently reports 45.17 deaths per 100,000 people against 44.32 deaths per 100,000 people in Mauritania, a difference of 0.85 deaths per 100,000 people.
Across all 22 years both countries report, Angola has been ahead every year.
Angola ranks 167th and Mauritania ranks 169th of 194 countries.
Angola has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Angola | Mauritania | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 53.82 deaths per 100,000 people | 41.92 deaths per 100,000 people | 11.9 deaths per 100,000 people | Angola |
| 2010s | 53.66 deaths per 100,000 people | 43.44 deaths per 100,000 people | 10.22 deaths per 100,000 people | Angola |
| 2020s | 47.42 deaths per 100,000 people | 43 deaths per 100,000 people | 4.42 deaths per 100,000 people | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Angola or Mauritania?
- Angola, at 45.17 deaths per 100,000 people against 44.32 deaths per 100,000 people in Mauritania as of 2021.
- What is the difference in death rate from cancer between Angola and Mauritania?
- 0.85 deaths per 100,000 people, with Angola ahead.
- How many years of comparable data are there for Angola and Mauritania?
- 22 years are reported by both, from 2000 to 2021.
- How do Angola and Mauritania rank globally for death rate from cancer?
- Angola ranks 167th and Mauritania ranks 169th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.